# Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

> **NCT00983255** · PHASE1 · COMPLETED · sponsor: **Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 90 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** TR-701 FA for injection, 200 mg/vial
- **DRUG:** TR-701 FA tablets

## Key facts

- **NCT ID:** NCT00983255
- **Lead sponsor:** Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983255, "Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00983255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*